Melodiol Global Health Limited

Corporate Update

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to provide the following corporate updates.


La Plata Facility

Further to ME1’s announcement on 4 September 2023, the Company provides the following update with respect to La Plata Capital, LLC’s (“La Plata”) secured note holding in the Company. Per the terms of the previous extension, ME1 was granted the option, subject to shareholder approval, to satisfy the October and November monthly interest payments to La Plata by the issue of fully paid ordinary shares (‘Shares’) at an issue price equal to the Company's closing Share price on the trading day immediately prior to issuance, based on a value ratio of 1.5 times the interest due. At the time, the Company also agreed to issue US$80,000 of shares using the same mechanism in order to begin paying down principal, starting in November 2023. In exchange for these concessions, the Company agreed to make a one time cash payment of US$160,000 to La Plata on or around 30 September 2023. Due to the large volume of corporate activity that has been undertaken by the Company, it was unable to achieve shareholder approval for these obligations prior to the commencement of the payment schedule. The Company has also not paid the modification fee to La Plata. In order to address this breach, the Company will has agreed to achieve shareholder approval by January 15, 2023, and adjust the value ratio from 1.5 times to 2.0 times for the October and November interest payments and November principal payments. The parties have also agreed that the Company may satisfy the US$160,000 modification fee and US$18,700 of legal fees by the issue of fully paid ordinary shares (‘Shares’) at an issue price equal to the Company's closing Share price on the trading day immediately prior to issuance, based on a value ratio of 2.0 times the interest due. The Company has also agreed to reduce the floor price from A$0.002 per Share to A$0.001 per Share.

Secured Notes

Further to the Company’s announcement dated 26 October 2023, the Company notes that the maturity date of the Secured Notes is 30 November 2023. The Company is engaged with the noteholders, with the objective of working towards a further extension, and will provide an update in due course.

Termination of Panacea Life Sciences Transaction and Rationalisation of Non-Core Business Units

Further to the Company’s announcements dated 2 August 2023 and 26 October 2023, the Company notes that on 4 December 2023, it terminated discussions with Panacea Life Sciences. The Company notes that several business units (Mernova Medicinal Inc., HealthHouse International, and Creso Pharma Switzerland) have demonstrated the ability to deliver cash flow positive results during FY23. With these encouraging results, the Company has taken active steps to refocus its efforts and resources into these higher performing business units, which in aggregate, represent 93% of group revenue (based on Q3 FY23). As part of that refocusing effort, the Company has temporarily paused operations at Halucenex Life Sciences, Sierra Sage Herbs, LLC, and impACTIVE Ltd. The Company has taken this decision in order to accelerate its ability to deliver group cash flow positive results and to concurrently pursue a sale of each of these non- core business units. Whilst it does so, it is likely that further capital will be required in the near term with the Company considering additional sources of capital, including but not limited to, further capital raising activities, divestment of non-core assets and possible divestment of core assets.


Click here for the full ASX Release

This article includes content from Melodiol Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

ME1:AU
The Conversation (0)
Melodiol Global Health

Melodiol Global Health


Keep reading...Show less

Global Portfolio of Strategic Cannabis and Plant-based Businesses

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming ArcStone-Kingswood Growth Summit in Toronto, taking place at the St. Regis Toronto on September 18, 2025. Dr. Frederick D Sancilio, CEO of lobe sciences ltd. will be presenting the company's recent milestones and future growth strategy.

The ArcStone-Kingswood Growth Summit will be hosting over 20 companies and a curated group of investors for a full day of pre-arranged, targeted 1-on-1 meetings, panel discussions and networking opportunities.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025.

This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America, which is anticipated to account for approximately 45 to 50 percent of this market.

The first half of 2025 was characterized by clinical advancements and softening policy stances, furthering momentum and contributing to growing market interest.

Keep reading...Show less
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Sunlit mushrooms growing on forest floor, backlit to show vibrant gills and earthy texture.

Psychedelics Market Forecast: Top Trends for Psychedelics in 2025

The psychedelics investment landscape enters 2025 on a complex path marked by both progress and setbacks.

While the US Food and Drug Association (FDA) continues to support research into the therapeutic potential of psychedelics, translating promising findings into approved treatments and accessible care is proving challenging.

This is evident in the recent legislative failures in Massachusetts and California, where initiatives aimed at expanding legal access to psychedelics were met with resistance. The FDA's August 2024 rejection of Lykos Therapeutics' midomafetamine for PTSD treatment underscores the rigorous standards required for regulatory approval.

Keep reading...Show less

Latest Press Releases

Related News

×